Status: Recruiting
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Participants needed: 35
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Bristol-Myers SquibbUpdated: Mar 30, 2026Locations: 4
Eligibility criteria
Participants must have completed Study IM011074 or Study IM011132 through the pr... [+2]
Participants must not have any disease or medical condition that, in the opinion... [+2]